Several brokerages have updated their recommendations and price targets on shares of NovaBay Pharmaceuticals (NYSEAMERICAN: NBY) in the last few weeks:

  • 11/15/2017 – NovaBay Pharmaceuticals had its price target lowered by analysts at Laidlaw from $10.00 to $8.00. They now have a “buy” rating on the stock.
  • 11/15/2017 – NovaBay Pharmaceuticals had its price target lowered by analysts at from $10.00 to $8.00. They now have a “buy” rating on the stock.
  • 11/15/2017 – NovaBay Pharmaceuticals was given a new $6.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/10/2017 – NovaBay Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 10/23/2017 – NovaBay Pharmaceuticals was given a new $5.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 10/12/2017 – NovaBay Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. “
  • 9/28/2017 – NovaBay Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. “

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN NBY) opened at $4.45 on Monday. NovaBay Pharmaceuticals, Inc. has a 52 week low of $2.25 and a 52 week high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last posted its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.09). NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%. The business had revenue of $4.09 million during the quarter, compared to the consensus estimate of $4.69 million.

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Receive News & Ratings for NovaBay Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.